Joseph Kupferman
Global Head of Renal & Clincial AstraZeneca
Seminars
Wednesday 18th March 2026
Advancing APOL1 Inhibition to Address High-Risk CKD Populations
11:00 am
- Reviewing the scientific rationale for targeting APOL1-driven kidney disease
- Translating genetic insights into therapeutic strategies for underserved patient groups
- Key learnings and progress from AstraZeneca’s APOL1 clinical development program
- Opportunities and challenges in biomarker-driven patient selection
